Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002770323 | SCV003029154 | uncertain significance | Nephronophthisis | 2022-11-22 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NPHP3 protein function. This variant has not been reported in the literature in individuals affected with NPHP3-related conditions. This variant is present in population databases (rs760443078, gnomAD 0.006%), including at least one homozygous and/or hemizygous individual. This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 708 of the NPHP3 protein (p.Thr708Ala). |
Ambry Genetics | RCV003375691 | SCV004094511 | uncertain significance | Inborn genetic diseases | 2023-08-14 | criteria provided, single submitter | clinical testing | The c.2122A>G (p.T708A) alteration is located in exon 15 (coding exon 15) of the NPHP3 gene. This alteration results from a A to G substitution at nucleotide position 2122, causing the threonine (T) at amino acid position 708 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |